These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39032786)

  • 1. Quercetin intervention reduced hepatic fat deposition in patients with nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled crossover clinical trial.
    Li N; Cui C; Xu J; Mi M; Wang J; Qin Y
    Am J Clin Nutr; 2024 Sep; 120(3):507-517. PubMed ID: 39032786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.
    Cusi K; Alkhouri N; Harrison SA; Fouqueray P; Moller DE; Hallakou-Bozec S; Bolze S; Grouin JM; Jeannin Megnien S; Dubourg J; Ratziu V
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):889-902. PubMed ID: 34560015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial).
    Ajmera VH; Cachay E; Ramers C; Vodkin I; Bassirian S; Singh S; Mangla N; Bettencourt R; Aldous JL; Park D; Lee D; Blanchard J; Mamidipalli A; Boehringer A; Aslam S; Leinhard OD; Richards L; Sirlin C; Loomba R
    Hepatology; 2019 Nov; 70(5):1531-1545. PubMed ID: 31013363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
    Guo W; Tian W; Lin L; Xu X
    Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
    Eriksson JW; Lundkvist P; Jansson PA; Johansson L; Kvarnström M; Moris L; Miliotis T; Forsberg GB; Risérus U; Lind L; Oscarsson J
    Diabetologia; 2018 Sep; 61(9):1923-1934. PubMed ID: 29971527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrogen-rich water reduces liver fat accumulation and improves liver enzyme profiles in patients with non-alcoholic fatty liver disease: a randomized controlled pilot trial.
    Korovljev D; Stajer V; Ostojic J; LeBaron TW; Ostojic SM
    Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):688-693. PubMed ID: 30982748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin supplementation alleviates hepatic fat content associated with modulation of gut microbiota-dependent bile acid metabolism in patients with nonalcoholic simple fatty liver disease: a randomized controlled trial.
    He Y; Chen X; Li Y; Liang Y; Hong T; Yang J; Cao Z; Mai H; Yao J; Zhang T; Wu K; Zou J; Feng D
    Am J Clin Nutr; 2024 Jul; 120(1):66-79. PubMed ID: 38795741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of Jian-Pi Huo-Xue granule for non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled trial.
    Sun Y; Chen G; Chen S; Wang Y; Hu Y; Zhao Y
    Trials; 2022 Jun; 23(1):455. PubMed ID: 35655225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety analysis of Danggui Shaoyao Powder for the treatment of non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled clinical trial.
    Huang Q; An Z; Xin X; Sun Q; Gao S; Lv S; Xu X; Yang S; Lu F; Yuan J; Zhao Y; Hu Y; Liu P; Feng Q
    BMC Complement Med Ther; 2023 Apr; 23(1):126. PubMed ID: 37076843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease.
    Ahn SB; Jun DW; Kang BK; Lim JH; Lim S; Chung MJ
    Sci Rep; 2019 Apr; 9(1):5688. PubMed ID: 30952918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
    Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
    J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial.
    Chooi YC; Zhang QA; Magkos F; Ng M; Michael N; Wu X; Volchanskaya VSB; Lai X; Wanjaya ER; Elejalde U; Goh CC; Yap CPL; Wong LH; Lim KJ; Velan SS; Yaligar J; Muthiah MD; Chong YS; Loo EXL; Eriksson JG;
    Am J Clin Nutr; 2024 Mar; 119(3):788-799. PubMed ID: 38035997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
    Harrison SA; Neff G; Guy CD; Bashir MR; Paredes AH; Frias JP; Younes Z; Trotter JF; Gunn NT; Moussa SE; Kohli A; Nelson K; Gottwald M; Chang WCG; Yan AZ; DePaoli AM; Ling L; Lieu HD
    Gastroenterology; 2021 Jan; 160(1):219-231.e1. PubMed ID: 32781086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of green coffee extract supplementation on serum adiponectin concentration and lipid profile in patients with non-alcoholic fatty liver disease: A randomized, controlled trial.
    Hosseinabadi S; Rafraf M; Asghari S; Asghari-Jafarabadi M; Vojouhi S
    Complement Ther Med; 2020 Mar; 49():102290. PubMed ID: 32147076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial.
    Stefan N; Ramsauer M; Jordan P; Nowotny B; Kantartzis K; Machann J; Hwang JH; Nowotny P; Kahl S; Harreiter J; Hornemann S; Sanyal AJ; Stewart PM; Pfeiffer AF; Kautzky-Willer A; Roden M; Häring HU; Fürst-Recktenwald S
    Lancet Diabetes Endocrinol; 2014 May; 2(5):406-16. PubMed ID: 24795254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial.
    Simon TG; Wilechansky RM; Stoyanova S; Grossman A; Dichtel LE; Lauer GM; Miller KK; Hoshida Y; Corey KE; Loomba R; Chung RT; Chan AT
    JAMA; 2024 Mar; 331(11):920-929. PubMed ID: 38502074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study.
    Oscarsson J; Önnerhag K; Risérus U; Sundén M; Johansson L; Jansson PA; Moris L; Nilsson PM; Eriksson JW; Lind L
    J Clin Lipidol; 2018; 12(6):1390-1403.e4. PubMed ID: 30197273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.